Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 68.78
CDXS's Cash-to-Debt is ranked higher than
51% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. CDXS: 68.78 )
Ranked among companies with meaningful Cash-to-Debt only.
CDXS' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.71  Med: No Debt Max: No Debt
Current: 68.78
Equity-to-Asset 0.62
CDXS's Equity-to-Asset is ranked lower than
56% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CDXS: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
CDXS' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.82  Med: 0.63 Max: 0.79
Current: 0.62
-1.82
0.79
Debt-to-Equity 0.01
CDXS's Debt-to-Equity is ranked higher than
97% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. CDXS: 0.01 )
Ranked among companies with meaningful Debt-to-Equity only.
CDXS' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.2  Med: -0.05 Max: 0.08
Current: 0.01
-0.2
0.08
Debt-to-EBITDA -0.03
CDXS's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. CDXS: -0.03 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CDXS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.66  Med: -0.51 Max: -0.03
Current: -0.03
-0.66
-0.03
Interest Coverage N/A
CDXS's Interest Coverage is ranked lower than
58% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CDXS: N/A )
Ranked among companies with meaningful Interest Coverage only.
CDXS' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: 3.11
Beneish M-Score: -1.15
WACC vs ROIC
-10.99%
-1363.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -40.89
CDXS's Operating Margin % is ranked higher than
59% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. CDXS: -40.89 )
Ranked among companies with meaningful Operating Margin % only.
CDXS' s Operating Margin % Range Over the Past 10 Years
Min: -151.36  Med: -28.36 Max: -6.65
Current: -40.89
-151.36
-6.65
Net Margin % -40.70
CDXS's Net Margin % is ranked higher than
58% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. CDXS: -40.70 )
Ranked among companies with meaningful Net Margin % only.
CDXS' s Net Margin % Range Over the Past 10 Years
Min: -153.86  Med: -29.71 Max: -7.97
Current: -40.7
-153.86
-7.97
ROE % -84.49
CDXS's ROE % is ranked lower than
71% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. CDXS: -84.49 )
Ranked among companies with meaningful ROE % only.
CDXS' s ROE % Range Over the Past 10 Years
Min: -84.49  Med: -37.42 Max: -15.76
Current: -84.49
-84.49
-15.76
ROA % -45.87
CDXS's ROA % is ranked lower than
60% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. CDXS: -45.87 )
Ranked among companies with meaningful ROA % only.
CDXS' s ROA % Range Over the Past 10 Years
Min: -52.02  Med: -25.02 Max: -7.11
Current: -45.87
-52.02
-7.11
ROC (Joel Greenblatt) % -549.31
CDXS's ROC (Joel Greenblatt) % is ranked lower than
54% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. CDXS: -549.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CDXS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -549.31  Med: -262.99 Max: -35.45
Current: -549.31
-549.31
-35.45
3-Year Revenue Growth Rate 12.90
CDXS's 3-Year Revenue Growth Rate is ranked higher than
65% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CDXS: 12.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CDXS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50 Max: 12.9
Current: 12.9
0
12.9
3-Year EBITDA Growth Rate -50.30
CDXS's 3-Year EBITDA Growth Rate is ranked lower than
94% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CDXS: -50.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CDXS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -52.5 Max: 33.7
Current: -50.3
0
33.7
3-Year EPS without NRI Growth Rate -42.10
CDXS's 3-Year EPS without NRI Growth Rate is ranked lower than
88% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. CDXS: -42.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CDXS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -47.2 Max: 45.6
Current: -42.1
0
45.6
GuruFocus has detected 6 Warning Signs with Codexis Inc CDXS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CDXS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CDXS Guru Trades in Q3 2016

Jim Simons 872,200 sh (+3.98%)
» More
Q4 2016

CDXS Guru Trades in Q4 2016

Jim Simons 859,100 sh (-1.50%)
» More
Q1 2017

CDXS Guru Trades in Q1 2017

Jim Simons 794,600 sh (-7.51%)
» More
Q2 2017

CDXS Guru Trades in Q2 2017

Jim Simons 766,700 sh (-3.51%)
» More
» Details

Insider Trades

Latest Guru Trades with CDXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:LSE:FARN, XBRU:TIG, SZSE:000004, XKRX:214450, OSTO:ONCO, XPAR:ERYP, ROCO:4128, XKRX:182400, OTCPK:AXIM, XKRX:141080, NAS:PTGX, XPAR:COX, NAS:SYBX, NAS:NERV, NAS:CERS, TSE:2183, TSE:4564, NAS:EDGE, NAS:ARWR, NAS:STML » details
Traded in other countries:4QK.Germany,
Headquarter Location:USA
Codexis Inc is a biotech company. It develops proprietary biocatalysts-enzymes or microbes that initiate or accelerate chemical reactions. It offers its products to the pharmaceutical industry. The company also develops advanced biofuels.

Codexis is a biotech company focused on developing proprietary biocatalysts--enzymes or microbes that initiate or accelerate chemical reactions. Codex markets its biocatalyst products to a range of customers, primarily within the pharmaceutical industry. The company is currently engaged in a multi-year research and development collaboration with Shell Oil Products to develop advanced biofuels.

Ratios

vs
industry
vs
history
PB Ratio 11.50
CDXS's PB Ratio is ranked lower than
82% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CDXS: 11.50 )
Ranked among companies with meaningful PB Ratio only.
CDXS' s PB Ratio Range Over the Past 10 Years
Min: 0.84  Med: 3.28 Max: 17.2
Current: 11.5
0.84
17.2
PS Ratio 7.24
CDXS's PS Ratio is ranked higher than
64% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. CDXS: 7.24 )
Ranked among companies with meaningful PS Ratio only.
CDXS' s PS Ratio Range Over the Past 10 Years
Min: 0.27  Med: 2.72 Max: 7.79
Current: 7.24
0.27
7.79
EV-to-EBIT -18.39
CDXS's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. CDXS: -18.39 )
Ranked among companies with meaningful EV-to-EBIT only.
CDXS' s EV-to-EBIT Range Over the Past 10 Years
Min: -125.2  Med: -9.4 Max: -0.4
Current: -18.39
-125.2
-0.4
EV-to-EBITDA -21.41
CDXS's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. CDXS: -21.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
CDXS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -644.8  Med: -10.4 Max: 439.2
Current: -21.41
-644.8
439.2
EV-to-Revenue 7.51
CDXS's EV-to-Revenue is ranked higher than
65% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. CDXS: 7.51 )
Ranked among companies with meaningful EV-to-Revenue only.
CDXS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2  Med: 2.4 Max: 7.9
Current: 7.51
0.2
7.9
Current Ratio 3.05
CDXS's Current Ratio is ranked lower than
61% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CDXS: 3.05 )
Ranked among companies with meaningful Current Ratio only.
CDXS' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.57 Max: 3.98
Current: 3.05
1.14
3.98
Quick Ratio 2.99
CDXS's Quick Ratio is ranked lower than
58% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. CDXS: 2.99 )
Ranked among companies with meaningful Quick Ratio only.
CDXS' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.46 Max: 3.75
Current: 2.99
1.07
3.75
Days Inventory 30.75
CDXS's Days Inventory is ranked higher than
84% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. CDXS: 30.75 )
Ranked among companies with meaningful Days Inventory only.
CDXS' s Days Inventory Range Over the Past 10 Years
Min: 30.75  Med: 45.73 Max: 66.14
Current: 30.75
30.75
66.14
Days Sales Outstanding 65.99
CDXS's Days Sales Outstanding is ranked higher than
51% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. CDXS: 65.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
CDXS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.19  Med: 48.52 Max: 92.67
Current: 65.99
31.19
92.67
Days Payable 112.04
CDXS's Days Payable is ranked higher than
71% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. CDXS: 112.04 )
Ranked among companies with meaningful Days Payable only.
CDXS' s Days Payable Range Over the Past 10 Years
Min: 43.52  Med: 166.88 Max: 253.68
Current: 112.04
43.52
253.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.50
CDXS's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CDXS: -2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CDXS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -143.1  Med: -2.4 Max: 0
Current: -2.5
-143.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 36.50
CDXS's Price-to-Net-Cash is ranked lower than
86% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. CDXS: 36.50 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CDXS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.45  Med: 11.46 Max: 105.75
Current: 36.5
3.45
105.75
Price-to-Net-Current-Asset-Value 16.59
CDXS's Price-to-Net-Current-Asset-Value is ranked lower than
74% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. CDXS: 16.59 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CDXS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.19  Med: 6.35 Max: 68.57
Current: 16.59
2.19
68.57
Price-to-Tangible-Book 12.81
CDXS's Price-to-Tangible-Book is ranked lower than
78% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. CDXS: 12.81 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CDXS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.34  Med: 4.06 Max: 23.76
Current: 12.81
1.34
23.76
Price-to-Median-PS-Value 2.66
CDXS's Price-to-Median-PS-Value is ranked lower than
87% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CDXS: 2.66 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CDXS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 1.03 Max: 2.79
Current: 2.66
0.12
2.79
Earnings Yield (Greenblatt) % -5.42
CDXS's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. CDXS: -5.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CDXS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -244.6  Med: -10.7 Max: -0.8
Current: -5.42
-244.6
-0.8

More Statistics

Revenue (TTM) (Mil) $43.16
EPS (TTM) $ -0.41
Beta-2.22
Short Percentage of Float5.55%
52-Week Range $3.60 - 7.95
Shares Outstanding (Mil)48.32

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 52 62 96 122
EPS ($) -0.31 -0.21 0.29 0.54
EPS without NRI ($) -0.31 -0.21 0.29 0.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}